Ekici, KemalOzsekee, NaciyeMayadagli, AlpaslanKocak, Mihriban ErdoganOlmezoglu, Ali2024-08-042024-08-0420141107-06252241-6293https://hdl.handle.net/11616/96668Purpose: To evaluate the efficacy and toxicity of CyberKnife stereotactic radiotherapy (SRT) for recurrent glial tumors previously treated with high-dose radiotherapy. Methods: CyberKnife SRT was performed in 37 patients with recurrent glial tumors who presented to our hospital between January 2007 and March 2012. The patients were subjected to a dose ranging from 20 to 28 Gy using the CyberKnife system with an average of two fractions. The median follow-up duration after SRT was 14 months (range 1.8-57). Results: The median survival time of the patients after recurrence was 22.3 months (95% confidence interval/95% Cl 12.5-32). The median survival times of the high- and low-grade patients were 29 and 19 months, respectively. No significant toxicity due to radiation was noticed during the follow-up period. No factor influencing mortality was found in either the univari ate or multivariate analysis.. Conclusion: SRT using CyberKnife is an effective and safe treatment choice for recurrent glial tumors. SRT achieves a more favorable outcome in the treatment of recurrent tumors, particularly in high-grade oneseninfo:eu-repo/semantics/closedAccessCyberKnifeglial tumorsrecurrencestereotactic radiosurgeryArticle19410291034255366122-s2.0-84921895244Q3WOS:000347742000026Q4